Profile
Christina Yi served as the Chief Operating Officer at Provention Bio, Inc. and Dendreon Pharmaceuticals LLC.
She also held the position of Chief Operating Officer at Vaxxinity, Inc. from 2020 to 2021.
In addition, she was the Chief Technology Officer at Alpine Immune Sciences, Inc. from 2023 to 2024.
Ms. Yi completed her undergraduate degree at the University of Washington.
Former positions of Christina Yi
| Companies | Position | End |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2024-05-19 |
| VAXXINITY, INC. | Chief Operating Officer | 2021-09-30 |
| PROVENTION BIO, INC. | Chief Operating Officer | - |
Dendreon Pharmaceuticals LLC
 Dendreon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Dendreon Pharmaceuticals LLC is a commercial-stage biopharmaceutical company that specializes in developing, manufacturing, and commercializing cell therapies. Dendreon Pharmaceuticals is based in Seal Beach, CA. The private company is a pioneer in cellular therapy, targeting cancer and transforming lives. Dendreon has proven expertise in cellular therapy and ensures product quality through its experience in the field. The company was founded in 1992 by Edgar G. Engleman and Samuel Strober, and the CEO is John C O'Neill. | Chief Operating Officer | - |
Training of Christina Yi
| University of Washington | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| VAXXINITY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Dendreon Pharmaceuticals LLC is a commercial-stage biopharmaceutical company that specializes in developing, manufacturing, and commercializing cell therapies. Dendreon Pharmaceuticals is based in Seal Beach, CA. The private company is a pioneer in cellular therapy, targeting cancer and transforming lives. Dendreon has proven expertise in cellular therapy and ensures product quality through its experience in the field. The company was founded in 1992 by Edgar G. Engleman and Samuel Strober, and the CEO is John C O'Neill. | Health Technology |
- Stock Market
- Insiders
- Christina Yi
